Vopimetostat

TNG-462 is an orally active and selective PRMT5 inhibitor with anti-tumor activity against methylthioadenosine phosphorylase (MTAP) deficiency and/or methylthioadenosine (MTA) accumulation cancers[1][2].

Product Specifications

CAS Number

[2760483-96-1]

Product Name Alternative

TNG-462

UNSPSC

12352005

Target

Histone Methyltransferase

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tng-462.html

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CCC1=CC(NC(C(N2[C@@H](C3=CC=C(SC(C4CCN(CC4)C)=N5)C5=C3)CC[C@@H](C2)C)=O)=O)=CN=C1N

Molecular Formula

C28H36N6O2S

Molecular Weight

520.69

References & Citations

[1]Briggs K, et al. TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors[J]. Cancer Research, 2023, 83 (7_Supplement) : 4970-4970.|[2]Kevin M Cottrell, et al. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers. Patent WO2022026892A1.